Trial Holdings Inc. (141A) AI Stock Analysis

• Market Cap: ¥251.99B
• Dividend Yield: 0.78%
• Average Volume (3M): 825.70K
• Price to Earnings (P/E): 21.4
• Beta (1Y): 0.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 6,529
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Discount Stores
• EPS (TTM): 27.62
• Shares Outstanding: 122,382,900
• 10 Day Avg. Volume: 925,780
• 30 Day Avg. Volume: 825,700
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ¥2,215.00 ▲(1.56% Upside)

The overall stock score of 58 reflects a combination of strong financial performance but significant technical weaknesses. The company's robust revenue growth and operational efficiency are overshadowed by cash flow challenges and bearish market momentum. The valuation suggests the stock may be overvalued, further impacting the score.

Trial Holdings Inc. Business Overview & Revenue Model

Company Description

Trial Holdings Inc. operates in the retail, logistics, financial / payment services, and retail tech businesses. The company operates discount-based stores that provide food, living ware, and home appliances. It also offers various solutions utilizing IoT devices, and software services. In addition, the company is involved in the real estate, restaurants, and resort businesses. The company was founded in 1974 and is based in Fukuoka, Japan.

How the Company Makes Money

Trial Holdings Inc. generates revenue through several key streams. Primarily, the company earns income from its clinical trial services, which include consulting fees for data management and patient recruitment. Additionally, Trial Holdings receives revenue from its investments in biotech firms, taking equity stakes in companies with promising drug candidates. These investments often yield returns through successful exits, either via public offerings or acquisitions. The company also benefits from strategic partnerships with pharmaceutical companies, which may involve joint ventures or collaborative projects that provide a share of profits from successful drug development.

Trial Holdings Inc. Financial Statement Overview

Summary

Trial Holdings Inc. shows strong revenue growth and operational efficiency, but profitability and cash flow management need improvement. The balance sheet remains robust, though increasing debt levels require attention. Overall, the company is on a stable trajectory but must address cash flow challenges to ensure long-term financial health.

Income Statement

Trial Holdings Inc. has demonstrated consistent revenue growth over the years, with a recent growth rate of 2.96%. The gross profit margin has improved to 20.78%, indicating efficient cost management. However, the net profit margin remains relatively low at 1.46%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are stable, reflecting operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has increased to 0.31, indicating a moderate level of leverage. Return on equity is strong at 9.32%, showcasing effective use of shareholder funds. The equity ratio stands at 42.00%, suggesting a solid capital structure. However, the increase in total debt warrants careful monitoring.

Cash Flow

The cash flow situation is concerning, with negative operating and free cash flows in the latest period. The free cash flow growth rate is negative, indicating cash flow challenges. The operating cash flow to net income ratio is negative, highlighting potential liquidity issues. Improvement in cash flow management is necessary.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	783.41B	806.59B	720.44B	655.48B	597.69B	157.93B
Gross Profit	158.78B	167.60B	144.84B	117.53B	103.49B	26.32B
EBITDA	30.34B	33.74B	30.78B	25.03B	21.58B	5.42B
Net Income	10.32B	11.75B	11.44B	8.08B	7.13B	1.85B
Balance Sheet
Total Assets	271.07B	300.28B	283.63B	200.64B	185.73B	171.44B
Cash, Cash Equivalents and Short-Term Investments	47.56B	72.33B	91.95B	23.90B	27.43B	22.74B
Total Debt	12.85B	38.58B	16.14B	19.61B	24.44B	27.94B
Total Liabilities	145.57B	171.25B	165.44B	132.62B	126.02B	118.65B
Stockholders Equity	122.67B	126.13B	115.68B	65.89B	57.96B	51.47B
Cash Flow
Free Cash Flow	0.00	-38.41B	36.84B	1.70B	9.39B	-7.14B
Operating Cash Flow	0.00	-4.45B	59.50B	18.45B	22.34B	-2.94B
Investing Cash Flow	0.00	-35.89B	-26.00B	-16.77B	-13.49B	-4.72B
Financing Cash Flow	0.00	20.77B	34.50B	-5.19B	-4.32B	-1.34B

Trial Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2181.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:141A, the sentiment is Negative. The current price of 2181 is below the 20-day moving average (MA) of 2189.65, below the 50-day MA of 2369.72, and below the 200-day MA of 2331.00, indicating a bearish trend. The MACD of -82.01 indicates Positive momentum. The RSI at 34.26 is Neutral, neither overbought nor oversold. The STOCH value of 9.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:141A.

Trial Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7646	―	¥14.40B	9.63	―	4.00%	-0.83%	367.39%
7451	―	―	―	―	―	1.49%	6.34%
3080	―	¥9.20B	48.90	―	1.79%	-1.36%	-63.23%
8203	―	¥26.12B	8.87	―	2.98%	6.70%	7.79%
Sector *	―	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
141A	―	¥251.99B	21.40	―	0.78%	―	―
2264	―	¥297.87B	39.99	―	2.71%	2.97%	-46.46%

Trial Holdings Inc. Corporate Events

Trial Holdings Inc. Reports Mixed Performance and Strategic Growth Plans

Trial Holdings Inc. reported mixed performance in recent months, with slight declines in customer traffic but an increase in average spending per customer, leading to stable sales figures. The company continues its strategic growth with new store openings and renovations, while also planning to disclose additional sales growth data starting in 2026, indicating a focus on transparency and expansion.

The most recent analyst rating on (JP:141A) stock is a Hold with a Yen2636.00 price target. To see the full list of analyst forecasts on Trial Holdings Inc. stock, see the JP:141A Stock Forecast page.

TRIAL Holdings Ensures Minority Shareholder Protection Amid Controlling Interest

TRIAL Holdings, Inc. has announced that THC Corporation, an asset management company owned by its director and family, holds a controlling interest with 53.97% of voting rights. The company emphasizes its commitment to protecting minority shareholders by adhering to strict regulations on related-party transactions, ensuring fairness and business necessity are reviewed by a dedicated committee.

The most recent analyst rating on (JP:141A) stock is a Hold with a Yen2636.00 price target. To see the full list of analyst forecasts on Trial Holdings Inc. stock, see the JP:141A Stock Forecast page.

TRIAL Holdings Reports Mixed Sales Amid Weather Challenges and Strategic Growth

TRIAL Holdings, Inc. reported fluctuations in sales and customer traffic, with a notable increase in average spending. Despite challenges from high comparative figures from the previous year and temporary store closures due to extreme weather, the company managed to maintain solid performance in fresh and ready meals, particularly during the Obon season. Non-food items showed mixed results, with declines in some categories but strong sales in summer apparel and bedding. The company continues to expand its store network with new openings and renovations.

The most recent analyst rating on (JP:141A) stock is a Buy with a Yen3166.00 price target. To see the full list of analyst forecasts on Trial Holdings Inc. stock, see the JP:141A Stock Forecast page.

TRIAL Holdings Reports 12% Sales Growth Amidst Liquidity Concerns

TRIAL Holdings, Inc. reported a 12% increase in net sales for the fiscal year ending June 30, 2025, reaching ¥803,829 million. Despite the growth in sales, the company’s profit attributable to owners rose modestly by 2.7% to ¥11,752 million. The company’s financial position showed improvement with an equity-to-asset ratio of 42% and net assets per share increasing to ¥1,031.30. However, cash flows from operating activities were negative at ¥4,446 million, indicating potential liquidity challenges. The company announced a slight increase in annual dividends per share from ¥15.00 to ¥16.00, reflecting a commitment to returning value to shareholders.

Trial Holdings Inc. Reports Strong Sales Growth and Strategic Expansion

Trial Holdings Inc. reported a steady increase in sales and average spending, despite a decline in customer traffic due to strategic gross profit growth initiatives. The company experienced strong demand for fresh and ready meals, particularly during the hot summer months, which contributed to the growth in same-store sales for 50 consecutive months. The company also expanded its footprint with five new store openings and no closures, while planning to disclose SEIYU’s sales growth data starting July 2026.